Maven Semantic: Phenotypic Screening Research Database

Search Over 32,000 People and Over 3,000 Phenotypic Screening Research Organisations

DUBLIN--(BUSINESS WIRE)-- Maven Semantic (http://www.mavensemantic.com) announces updates to their Phenotypic Screening research database.

The new database is now available to marketing, business development, competitor intelligence, KOL, medical affairs and related departments in the life sciences sector.

The database currently tags 32,000 individuals working in Phenotypic Screening. http://bit.ly/dcov1m .

High Content screening is also known as cell based screening, phenotypic screening or visual screening, and it has a major place in pharmaceutical company drug discovery. All these terms refer to the systematic search for new drugs, small molecule inhibitors or chemical entities that could have use in biology or medicine.

Top 10 Countries for Phenotypic Screening Research (ranked by number of senior Phenotypic Screening researchers)

. United States Of America (12,506)

. United Kingdom (2,472)

. Germany (1,988)

. Japan (1,701)

. France (1,443)

. Italy (1,271)

. Canada (1,122)

. The Netherlands (814)

. China (774)

. Australia (676)

Leading organisations in Phenotypic Screening research include:

. University of California

. National Institutes of Health

. Harvard Medical School

. Baylor College of Medicine

. Washington University School of Medicine

. Howard Hughes Medical Institute

. University of Toronto

. University of Washington

. Duke University Medical Center

. University of Minnesota

. University of Cambridge

. University of Oxford

. Johns Hopkins University School of Medicine

. University of British Columbia

. Massachusetts General Hospital

. National Cancer Institute

. Yale University School of Medicine

. Massachusetts Institute of Technology

. Institut Pasteur

. Columbia University

. The Scripps Research Institute

. Institute of Human Genetics

. Centers for Disease Control and Prevention

. Fred Hutchinson Cancer Research Center

. Mount Sinai School of Medicine

. Case Western Reserve University

. Michigan State University

. Seoul National University

. University of Georgia

. Institute of Child Health

. King's College London

The database also includes pharmaceutical companies, biotech companies, CROs, hospitals, government labs and other organisations active in the Phenotypic Screening research field.

Sample companies in database include:

. Morphochem Inc

. Japan Science and Technology Corporation

. Essential Therapeutics, Inc

. Ingenium Pharmaceuticals AG

. PathoGenesis Corporation

. Pfizer Inc

. Rosetta Inpharmatics, LLC

. Translational and Clinical Research, Inc

. Novartis Pharma AG

. Xantos Biomedicine AG

. Novozymes Biopharma UK Ltd

. Cenix BioScience GmbH

. Cytokinetics Inc

. Eli Lilly and Company

. New England Biolabs, Inc

. AntiCancer, Inc

. Corixa Corporation

. CropDesign N.V

. Genentech, Inc

. Genome Therapeutics Corporation

. Nestec Ltd

. Achaogen, Inc

. Bayer Schering Pharma AG

. Bristol-Myers Squibb Company

What is Maven:

- Largest database of international medical professionals, with over 6,000,000 people and over 500,000 medical organisations;

- All records are downloadable to excel or in-house database, with email, postal address and phone contacts;

- Profile and segment the entire database using over 47,000 diseases and therapeutic areas

What is Maven used for:

- Building prospect lists for postal, telesales and email campaigns

- Locating key decision makers in companies, hospitals, government labs, university labs, and other healthcare facilities

- Identifying candidates for recruitment to very specific life science positions

About the Maven Semantic Medical Database: The current database holds over 6 million medical professionals, and 500,000 medical organisations.

The Maven Semantic medical database covers pharmaceutical, biotech and medical device companies, clinical research labs, hospitals, medical universities and government research organisations.

Maven is a SaaS subscription-based service. Clients can choose from quarterly or yearly subscriptions, or as pay-as-you-go option to retrieve specific large datasets for in-house use.

Results can be viewed online, or exported to Excel or a CRM system.

The data is now available to international healthcare marketing teams.

About our Technology: Semantic data mining tools have been used to create a database of detailed profiles of life science companies and executives.

The system uses the open web as an underlying database and extracts specific information on people, job titles, biographies, research profiles, contact details (dept., phone, fax, and email), organisation profiles, websites, product/services and much more.

Maven is based on healthcare crawlers/bots, search technology, semantic parsers, clustering, natural language processing (NLP) and artificial intelligence (AI) technology.

"The system uses the context in which a given person appears, using artificial intelligence techniques to find out information not otherwise visible - for example, how important is this person in a specific medical research specialization," says Alejandro Mesas, Semantic Systems Architect. "The big advantage of a focused semantic healthcare database over a generic search engine is that it has built-in taxonomies and a thesaurus to expand and refine the user queries. We then use scoring and ranking to fine tune the relevance of the results for a given therapeutic area. For example, stem cell researchers are given a "page rank", based on where they work, their job title, how many times they have published, where they have published, etc. The relevance can be fine tuned by the user".

For more information visit http://www.mavensemantic.com/



CONTACT:

Maven Semantic
Bryan McManmon
[email protected]
Ph: + 353 1 4100699

KEYWORDS:   Australia  United States  Europe  Asia Pacific  North America  Australia/Oceania

INDUSTRY KEYWORDS:   Health  Biotechnology  Hospitals  Pharmaceutical  Other Health

MEDIA:

Logo
 Logo

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.